Neumora Therapeutics (NMRA) EBIT (2022 - 2026)
Neumora Therapeutics' (NMRA) quarterly EBIT came in at -$52.9 million in Q1 2026, up 25.48% year-on-year from -$42.1 million in Q1 2025, and up 9.6% quarter-over-quarter from -$58.5 million in Q4 2025.
Neumora Therapeutics (NMRA) EBIT (2022 - 2026) Analysis & Trends
Neumora Therapeutics' EBIT history runs 5 years deep, the most recent figure standing at -$52.9 million for Q1 2026.
- On a quarterly basis, EBIT rose 25.48% year-over-year to -$52.9 million in Q1 2026; TTM through Mar 2026 was -$223.1 million, a 18.68% increase from a year earlier, with the FY2025 full-year figure at -$241.2 million, up 8.47% from the prior year.
- EBIT improved to -$52.9 million in Q1 2026 per NMRA's latest filing, from -$58.5 million in the prior quarter.
- Across five years, EBIT topped out at -$30.6 million in Q3 2022 and bottomed at -$114.0 million in Q4 2023.
- The 5-year median for EBIT is -$57.7 million (2025), against an average of -$58.1 million.
- Across the five-year window, EBIT sank 271.13% in 2023 and surged 44.81% in 2024, its largest moves.
- Year by year, EBIT stood at -$30.7 million in 2022, then sank by 271.13% to -$114.0 million in 2023, then jumped by 44.81% to -$62.9 million in 2024, then climbed by 7.06% to -$58.5 million in 2025, then rose by 9.6% to -$52.9 million in 2026.
- Per Business Quant, the three latest NMRA EBIT figures stand at -$52.9 million (Q1 2026), -$58.5 million (Q4 2025), and -$57.7 million (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -27.75 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -15.76 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 249.90 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.14 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 642.90 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -32.68 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 394.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -445.22 Mn |
| 10 | Neumora Therapeutics | 270.71 Mn | 270.71 Mn | - | -52.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -52.86 Mn |
| Dec 31, 2025 | -58.48 Mn |
| Sep 30, 2025 | -57.70 Mn |
| Jun 30, 2025 | -54.04 Mn |
| Mar 31, 2025 | -70.94 Mn |
| Dec 31, 2024 | -62.92 Mn |
| Sep 30, 2024 | -76.65 Mn |
| Jun 30, 2024 | -63.82 Mn |
| Mar 31, 2024 | -60.07 Mn |
| Dec 31, 2023 | -114.00 Mn |
| Sep 30, 2023 | -56.86 Mn |
| Jun 30, 2023 | -42.06 Mn |
| Mar 31, 2023 | -39.17 Mn |
| Dec 31, 2022 | -30.72 Mn |
| Sep 30, 2022 | -30.60 Mn |